Exane Derivatives’s Federal Realty Investment Trust FRT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q2
$96 Buy
+1
New +$112 ﹤0.01% 717
2021
Q4
Sell
-1
Closed -$118 913
2021
Q3
$118 Hold
1
﹤0.01% 1022
2021
Q2
$117 Hold
1
﹤0.01% 1027
2021
Q1
$101 Hold
1
﹤0.01% 860
2020
Q4
$85 Hold
1
﹤0.01% 805
2020
Q3
$73 Hold
1
﹤0.01% 733
2020
Q2
$85 Hold
1
﹤0.01% 668
2020
Q1
$75 Hold
1
﹤0.01% 677
2019
Q4
$128 Hold
1
﹤0.01% 653
2019
Q3
$136 Hold
1
﹤0.01% 633
2019
Q2
$129 Hold
1
﹤0.01% 633
2019
Q1
$138 Hold
1
﹤0.01% 572
2018
Q4
$118 Hold
1
﹤0.01% 637
2018
Q3
$124 Hold
1
﹤0.01% 614
2018
Q2
$127 Buy
+1
New +$118 ﹤0.01% 602
2017
Q2
Sell
-1
Closed -$133 652
2017
Q1
$133 Hold
1
﹤0.01% 480
2016
Q4
$142 Hold
1
﹤0.01% 525
2016
Q3
$154 Buy
+1
New +$162 ﹤0.01% 518

Other funds holding FRT

Exane Derivatives's FRT Position: Q2 2022 in Review

Exane Derivatives opened a new position in Federal Realty Investment Trust (FRT) in Q2 2022: 1 share worth $96. The stake represents ﹤0.01% of the portfolio and ranks #717 among its holdings. This is a return to the name: Exane Derivatives previously reported a position in FRT as recently as Q3 2021.

Exane Derivatives first reported a position in FRT in Q3 2016 and has held it in 18 quarters since. The position peaked at $154 in Q3 2016. 401 funds tracked by Wall St. Rank hold FRT as of Q2 2022.

  • Exane Derivatives held 1 share of Federal Realty Investment Trust worth $96 as of Q2 2022.
  • Federal Realty Investment Trust was a new Exane Derivatives position in Q2 2022.
  • Federal Realty Investment Trust made up ﹤0.01% of Exane Derivatives's portfolio in Q2 2022, its #717 holding.
  • Exane Derivatives first reported a position in Federal Realty Investment Trust in Q3 2016 and has held it in 18 quarters since.
  • Exane Derivatives's Federal Realty Investment Trust position peaked at $154 in Q3 2016.
  • 401 funds tracked by Wall St. Rank held Federal Realty Investment Trust as of Q2 2022.

Based on Exane Derivatives's 13F filing for Q2 2022, filed 12 Jul 2022.